#433: AI Could Transform The Software Value Chain, & More
Anthropic—the AI development company behind the top-tier Claude models—is reportedly seeking a valuation as high as $40 billion in a new fundraising round. In the wake of OpenAI’s ongoing efforts to raise $6-7 billion at a valuation of ~$150 billion, Anthropic’s talks with investors are still in early stages. These reports are leading to questions about the justification for these lofty valuations.
Carnival Corp. (CCL) Q3 2024 Earnings Call Transcript
CCL earnings call for the period ending June 30, 2024.
Is Kinder Morgan Stock a Buy?
Kinder Morgan has a big yield and reliable cash flows. But you have to overlook one big issue if you plan on buying the stock.
Down 90% From the Highs, This Stock Could Be a Big Winner of the Fed’s Rate Cut
This fintech disruptor has already rebounded sharply, but it could be just the beginning.
Billionaire Bill Ackman Has Close to 20% of His Portfolio in 1 Magnificent Travel Stock
The investor is closely tracked and has owned this stock for many years.
Like Occidental Petroleum? You Should Check Out This Oil Stock.
Diamondback Energy has some attractive qualities.
Worried About a Stock Market Pullback? Buy This Vanguard ETF.
The stock market seems due for a rotation.
2 Magnificent Growth Stocks Down 45% and 32% to Buy Right Now
Sometimes, a discounted stock can present a valuable opportunity.
Near a 52-Week Low and Buying Back Shares, Is Iridium Stock a Buy?
Iridium will use a stock buyback program to turn its single-digit growth rate into a double-digit growth rate.
Micron Shares Surge on Outlook, Defying Analyst Expectations. Is the Stock a Buy Now?
There is still one area investors need to monitor closely.
The Fed Just Lowered Interest Rates. My Top High-Yield Dividend Stock to Buy Now.
Lower interest rates make dividend stocks more desirable.
Is Ultra-High-Yield Annaly Capital Management Stock a Buy?
Annaly Capital looks appealing because of its huge dividend yield, but it isn’t an income stock when you look more closely.
Is Summit Therapeutics Stock a Buy?
Its alliance with a successful foreign biotech could be decisive for the stock.
The S&P 500 Is Rebounding: 2 Tech Stocks to Buy Now, According to These Wall Street Analysts
Here are two reasonably priced growth tech stocks that could soar in 2025.